Median Technologies Lands €8.4M Oncology Imaging Deal for Global Phase III Trial
Event summary
- Median Technologies secured an €8.4M contract for central imaging services in a global Phase III brain cancer trial.
- The project involves over 150 investigator sites across four continents.
- The deal represents one of the largest in Median's iCRO business unit history.
- The study evaluates an investigational treatment for a rare form of brain cancer.
The big picture
This deal underscores the growing demand for AI-powered imaging services in oncology clinical trials, particularly for rare and challenging cancers. Median's ability to secure large-scale, strategic programs from leading pharmaceutical companies highlights the increasing importance of specialized imaging partners in accelerating drug development. The contract's significant value and global scope further validate the company's focus on complex oncology imaging programs.
What we're watching
- Revenue Visibility
- How this €8.4M deal will impact Median's revenue visibility and order backlog.
- Strategic Positioning
- Whether Median can sustain its position as a trusted imaging partner for complex global oncology trials.
- Operational Execution
- The pace at which Median can deliver advanced 3D image analysis and operational coordination across diverse investigator sites.
Related topics